ClinicalTrials.gov
Official API · multinational records · source links on every study
Official registry discovery
Global Phase I-III
drug opportunity library.
Discover active drug and biologic programs, trace every record to its official source, and prioritize BD review without confusing signals with clinical proof.
Livematching registry studies
3selected clinical phases
OfficialClinicalTrials.gov source
On loadretrieval time
Registry presence does not confirm efficacy, ownership, regulatory success, commercial value, or licensing status.
AI evidence synthesis
Evidence-bound synthesis will appear only after a project passes every deterministic gate.
Risks and disconfirming evidence
Unavailable until complete official evidence is validated.
Next diligence actions
No action is generated from partial coverage.
AI INVESTMENT RESEARCH WATCH
AI Investment Spotlight
One project may be selected only after the full eligible Phase I-III universe and every evidence gate have been processed.
Full-universe scan coverageStartingPartial coverage — selection withheld
Complete-universe screening in progress
Selection is withheld until the evidence gates are satisfied.
The first durable scan batch will start when this page connects to the analysis service.
Asset/BD attention score—/100Awaiting complete evidence
Equity research attention score—/100Awaiting verified issuer mapping
ClinicalTrials.govlivePubMedconfiguration requiredopenFDA / Drugs@FDAliveEMAconfiguration requiredSEC EDGARconfiguration requiredWHO ICTRPmanualEU CTISmanual
Market valuation data not connected
Human review and explicit approval are required before any investment, licensing, transaction, outreach, or other external action.
EXPANDED PROJECT COLLECTION
Registry snapshot …Phase III: ongoing & completed
Evidence-reviewed novel molecules and biologics, with a separate registry screening pool.
— evidence-reviewed development assets— registry trial records— completed trials in the screening pool
A completed trial does not establish success or approval. The registry pool includes established drugs, comparators and biosimilars; its records are pending innovation review and are not counted as verified innovative assets. Licensing availability, territory rights and intermediary mandate remain pending verification.
Loading collection records…
Page 1 of 1
ACTIVE DEVELOPMENT SIGNALS
Phase I-III opportunities
Live public registry records
Expression of Interest: Product Licensing (In/Out) and M&A Opportunities (Represented by BIOPHARMA PTE. LTD. as Intermediary). Use non-confidential information only for any listed project. Submission does not guarantee a response, cooperation, acquisition, or transaction.
BIOPHARMA PTE. LTD. acts as a bridge between both parties and uses reasonable efforts to facilitate cooperation. However, not every opportunity will result in a successful collaboration or transaction.
SOURCE COVERAGE
Global discovery, with the gaps visible.
ClinicalTrials.gov contains multinational studies and is refreshed by its operator on business days, but it is not exhaustive of all global registries. PharmaBridge shows what is live and what still needs integration.
EU CTIS
European Union source · not yet normalized into this library
WHO ICTRP
Global registry network · separate search and verification required
National registries
Jurisdiction-specific sources require additional data work
AUDITABLE TRIAGE
What the score means—and what it does not.
Registry facts
Phase, status, sponsor, locations, enrollment, intervention, and update date come from the official public record.
Platform signals
The priority score summarizes maturity, activity, freshness, geography, and record completeness for BD triage.
Human diligence
No score establishes efficacy, approval, valuation, freedom to operate, asset ownership, or commercial availability.